This trial is designed to evaluate the safety and effectiveness of transplanting retinal pigment epithelial cells (RPE) in patients with wet age-related macular degeneration in whom there is rapidly progressing vision loss. The trial is being conducted at University College, London, in conjunction with Pfizer. Participants will receive the RPE cells, which have been made from human embryonic stem cells, embedded on a membrane which will be inserted into the eye. Participants will be monitored for complications including infection and tumour growth, as well as structural evidence of successful engraftment and changes to vision. The trial is not yet open but expects to enrol 10 subjects by December 2015.